Raymond James & Associates’s Axsome Therapeutics AXSM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $782K | Buy |
8,701
+58
| +0.7% | +$5.21K | ﹤0.01% | 2829 |
|
|
2024
Q2 | $696K | Sell |
8,643
-186
| -2% | -$15K | ﹤0.01% | 2842 |
|
|
2024
Q1 | $705K | Buy |
8,829
+3,412
| +63% | +$272K | ﹤0.01% | 2821 |
|
|
2023
Q4 | $431K | Sell |
5,417
-51
| -0.9% | -$4.06K | ﹤0.01% | 3025 |
|
|
2023
Q3 | $382K | Sell |
5,468
-2,603
| -32% | -$182K | ﹤0.01% | 3030 |
|
|
2023
Q2 | $580K | Buy |
8,071
+3,100
| +62% | +$223K | ﹤0.01% | 2822 |
|
|
2023
Q1 | $307K | Sell |
4,971
-1,923
| -28% | -$119K | ﹤0.01% | 3202 |
|
|
2022
Q4 | $532K | Buy |
6,894
+973
| +16% | +$75K | ﹤0.01% | 2848 |
|
|
2022
Q3 | $264K | Buy |
5,921
+15
| +0.3% | +$669 | ﹤0.01% | 3240 |
|
|
2022
Q2 | $226K | Buy |
5,906
+277
| +5% | +$10.6K | ﹤0.01% | 3398 |
|
|
2022
Q1 | $233K | Buy |
5,629
+195
| +4% | +$8.07K | ﹤0.01% | 3544 |
|
|
2021
Q4 | $205K | Buy |
+5,434
| New | +$205K | ﹤0.01% | 3654 |
|
|
2021
Q3 | – | Sell |
-7,134
| Closed | -$481K | – | 3937 |
|
|
2021
Q2 | $481K | Buy |
7,134
+3,298
| +86% | +$222K | ﹤0.01% | 3087 |
|
|
2021
Q1 | $217K | Hold |
3,836
| – | – | ﹤0.01% | 3522 |
|
|
2020
Q4 | $313K | Sell |
3,836
-167
| -4% | -$13.6K | ﹤0.01% | 3079 |
|
|
2020
Q3 | $285K | Hold |
4,003
| – | – | ﹤0.01% | 2967 |
|
|
2020
Q2 | $329K | Sell |
4,003
-264
| -6% | -$21.7K | ﹤0.01% | 2848 |
|
|
2020
Q1 | $251K | Sell |
4,267
-3,408
| -44% | -$200K | ﹤0.01% | 2871 |
|
|
2019
Q4 | $793K | Sell |
7,675
-15,696
| -67% | -$1.62M | ﹤0.01% | 2413 |
|
|
2019
Q3 | $473K | Sell |
23,371
-2,000
| -8% | -$40.5K | ﹤0.01% | 2680 |
|
|
2019
Q2 | $653K | Buy |
+25,371
| New | +$653K | ﹤0.01% | 2477 |
|